<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04285450</url>
  </required_header>
  <id_info>
    <org_study_id>CL2182</org_study_id>
    <nct_id>NCT04285450</nct_id>
  </id_info>
  <brief_title>The Clinical Effect of Vitamin K Administration in Type 2 Diabetic Patients</brief_title>
  <official_title>The Clinical Effect of Vitamin K Administration in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to examine the possible clinical effects associated with vitamin K
      supplementation on the glycemic control, insulin sensitivity and lipid profile of type II
      diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Homeostasis model assessment of insulin resistance (HOMA-IR)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Vitamin K 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin K</intervention_name>
    <description>1mg</description>
    <arm_group_label>Vitamin K 1mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lactose</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients 21-65 years old diagnosed with Type II diabetes.

          -  Fasting blood glucose concentration ≥ 126 mg/dL .

          -  Normal liver Function tests defined as ALT levels up to 33 U/L for males and up to 25
             U/L for females, Albumin levels ≥ 3.5 g/dL, Bilirubin up to 1.1 mg/dL .

          -  Normal clotting function defined as defined by INR.

          -  Normal kidney function defined as serum creatinine values up to 1.3 mg/dL.

        Exclusion Criteria:

          -  Type I diabetic patients.

          -  Use of supplements with potential effect on vitamin K level namely supplements
             containing vitamin K, co-enzyme Q10 or vitamin E &gt; 400 IU .

          -  Patients requiring anti-coagulant therapy including patients with prosthetic valves,
             mitral tissues, DVT, PE, atrial fibrillation and valvular heart disease.

          -  Patient with history of coagulation, MI, stroke and embolization.

          -  Pregnant or breast feeding women.

          -  Being on hormonal therapy or receiving contraceptive pills.

          -  Patients treated with glucocorticoids, thiazide diuretics, and atypical
             antipsychotics.

          -  Patients on cholestyramine, antibiotics and coumarins.

          -  Patients on lipid lowering agents.

          -  Known intestinal malabsorption syndrome, cholestasis or steatorrhea.

          -  Smokers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amani Ahmed</last_name>
    <phone>01002739446</phone>
    <email>amany.mohamed@pharma.cu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kasr Al Aini Hospital</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amani Ahmed</last_name>
      <phone>01002739446</phone>
      <email>amany.mohamed@pharma.cu.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 17, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Amani Mohamed</investigator_full_name>
    <investigator_title>Assistant Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin K</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

